ORLANDINI MAURIZIO

Maurizio
Orlandini
Dipartimento di Biotecnologie, Chimica e Farmacia
Professore Associato

Office hours

  • Tuesday from 09:00 to 12:00
    Place: Ufficio A_03_53
    Note: Contattare preventivamente il docente

Office A_03_53

Contacts

maurizio.orlandini@unisi.it
0577232065 [int.2065]

Curriculum Vitae

cv

Teaching activities

Completion accademic year: 2026/2027

MOLECULAR BIOLOGY
Course year: 4 Full cicle (5 years) CHIMICA E TECNOLOGIA FARMACEUTICHE A.Y. 2023/2024
MOLECULAR BIOLOGY OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2026/2027
MOLECULAR BIOLOGY OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2026/2027
MOLECULAR BIOLOGY OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2026/2027
RATIONAL TREATMENT OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2026/2027

Completion accademic year: 2025/2026

MOLECULAR BIOLOGY
Course year: 4 Full cicle (5 years) PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY A.Y. 2022/2023
MOLECULAR BIOLOGY OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2025/2026
RATIONAL TREATMENT OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2025/2026

Completion accademic year: 2024/2025

MOLECULAR BIOLOGY
Course year: 4 Full cicle (5 years) PHARMACEUTICAL CHEMISTRY AND TECHNOLOGY A.Y. 2021/2022
MOLECULAR BIOLOGY OF CANCER
Course year: 1 Second cycle degree (Laurea Magistrale) SUSTAINABLE INDUSTRIAL PHARMACEUTICAL BIOTECHNOLOGY A.Y. 2024/2025

Registration for exams

Research

Ultime pubblicazioni:

  • Perrone, C.D., Raucci, L., Papini, S., Tosi, G.M., Galvagni, F., Olivucci, M., et al. (2026). Rational design of hammerhead ribozymes as CD93 silencing tools for vascular diseases. MOLECULAR THERAPY NUCLEIC ACIDS, 37(2) [10.1016/j.omtn.2026.102968]. - view more
  • Paolino, M., Tassone, G., Governa, P., Saletti, M., Lami, M., Carletti, R., et al. (2025). Morita−Baylis−Hillman Adduct Chemistry as a Tool for the Design of Lysine-Targeted Covalent Ligands. ACS MEDICINAL CHEMISTRY LETTERS, 16(3), 397-405 [10.1021/acsmedchemlett.4c00479]. - view more
  • Orlandini, M. (2025). Cellular role of CD93 and its potential as a future therapeutic target. EXPERT OPINION ON THERAPEUTIC TARGETS, 29(4-5), 179-183 [10.1080/14728222.2025.2500427]. - view more
  • Frusciante, L., Nyong'A, C.N., Trezza, A., Shabab, B., Olmastroni, T., Barletta, R., et al. (2025). Bioactive Potential of Sweet Cherry (Prunus avium L.) Waste: Antioxidant and Anti-Inflammatory Properties for Sustainable Applications. FOODS, 14(9) [10.3390/foods14091523]. - view more
  • El-Khawaga, A.M., Orlandini, M., Raucci, L., Elmaghraby, K. (2025). Magnetic nanoparticles as a promising antimicrobial agent for combating multidrug resistant bacteria: a review. DISCOVER APPLIED SCIENCES, 7(7) [10.1007/s42452-025-06601-5]. - view more
All publications